• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第一代氨基双膦酸盐:一类新型的胃肠毒性药物——阿仑膦酸盐与阿司匹林的比较

Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.

作者信息

Graham D Y, Malaty H M, Goodgame R

机构信息

Department of Medicine, Veterans Affairs Medical Center, and Baylor College of Medicine, Houston, Texas 77030, USA.

出版信息

Am J Gastroenterol. 1997 Aug;92(8):1322-5.

PMID:9260798
Abstract

BACKGROUND

Alendronate and pamidronate are primary amino-bisphosphonates used in the treatment of metabolic bone disease. Both drugs have been associated with reversible erosive esophagitis and as a result pamidronate is approved in the United States only for parenteral use. In rats, alendronate causes acute gastric mucosal damage similar to that seen with aspirin or nonsteroidal anti-inflammatory drugs.

METHODS

We performed a blinded, crossover, randomized, single-center, placebo-controlled, endoscopic comparison of alendronate (40 mg/day), aspirin (1, 300 mg/day), and placebo to evaluate the presence and degree of mucosal damage to the esophagus, stomach, and duodenal bulb.

RESULTS

Twelve normal healthy volunteers were studied both before and after 4 days of drug therapy. Placebo caused no visible endoscopic damage. In contrast, both aspirin and alendronate were associated with visible gastric mucosal injury in the majority of those studied (75 and 58%, respectively) and both were significantly greater than placebo (p < 0.001). The gastric mucosal injury was deemed severe in 50% of those receiving alendronate or aspirin; one alendronate-associated gastric ulcer was seen. Esophageal and duodenal bulb injury was seen once each, and both were associated with alendronate.

CONCLUSIONS

The primary amino-bisphosphonate alendronate causes mucosal injury to the upper gastrointestinal tract similar to aspirin. Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution.

摘要

背景

阿仑膦酸盐和帕米膦酸盐是用于治疗代谢性骨病的伯氨基双膦酸盐。这两种药物都与可逆性糜烂性食管炎有关,因此帕米膦酸盐在美国仅被批准用于肠胃外给药。在大鼠中,阿仑膦酸盐会导致急性胃黏膜损伤,类似于阿司匹林或非甾体类抗炎药所造成的损伤。

方法

我们进行了一项双盲、交叉、随机、单中心、安慰剂对照的内镜比较研究,对比阿仑膦酸盐(40毫克/天)、阿司匹林(1300毫克/天)和安慰剂,以评估食管、胃和十二指肠球部黏膜损伤的存在情况及程度。

结果

12名正常健康志愿者在药物治疗4天前后均接受了研究。安慰剂未造成可见的内镜损伤。相比之下,在大多数接受研究的受试者中,阿司匹林和阿仑膦酸盐均与可见的胃黏膜损伤有关(分别为75%和58%),且二者均显著高于安慰剂(p < 0.001)。在接受阿仑膦酸盐或阿司匹林治疗的受试者中,50%的人胃黏膜损伤被认为较为严重;观察到1例与阿仑膦酸盐相关的胃溃疡。食管和十二指肠球部损伤各出现1次,且均与阿仑膦酸盐有关。

结论

伯氨基双膦酸盐阿仑膦酸盐会导致上消化道黏膜损伤,与阿司匹林类似。即使按照制造商的给药说明使用,阿仑膦酸盐可能也应谨慎使用。

相似文献

1
Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.第一代氨基双膦酸盐:一类新型的胃肠毒性药物——阿仑膦酸盐与阿司匹林的比较
Am J Gastroenterol. 1997 Aug;92(8):1322-5.
2
Effects of alendronate on gastric and duodenal mucosa.阿仑膦酸钠对胃和十二指肠黏膜的影响。
Am J Gastroenterol. 1998 May;93(5):753-7. doi: 10.1111/j.1572-0241.1998.219_a.x.
3
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.阿仑膦酸钠在临床上有胃肠道毒性吗?回复:格雷厄姆等人。伯氨基双膦酸盐:一类新的具有胃肠道毒性的药物——阿仑膦酸钠与阿司匹林的比较。
Am J Gastroenterol. 1998 Feb;93(2):284-5. doi: 10.1111/j.1572-0241.1998.281_8_8.x.
4
Upper gastrointestinal toxicity of alendronate.阿仑膦酸盐的上消化道毒性。
Am J Gastroenterol. 2000 Mar;95(3):634-40. doi: 10.1111/j.1572-0241.2000.01835.x.
5
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.一项为期14天的内镜研究,比较了在按幽门螺杆菌感染状况分层的绝经后妇女中利塞膦酸盐和阿仑膦酸盐的效果。
J Rheumatol. 2002 Sep;29(9):1965-74.
6
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.阿仑膦酸盐和利塞膦酸盐对上部胃肠道黏膜影响的内镜比较。
Am J Gastroenterol. 2000 Nov;95(11):3112-7. doi: 10.1111/j.1572-0241.2000.03258.x.
7
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.每周一次口服70毫克阿仑膦酸钠的上消化道安全性和耐受性:一项安慰剂对照的内镜研究。
Am J Gastroenterol. 2002 Jan;97(1):58-64. doi: 10.1111/j.1572-0241.2002.05446.x.
8
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.每周一次服用70毫克阿仑膦酸钠并同时使用非甾体抗炎药时的上消化道耐受性。
Aliment Pharmacol Ther. 2005 Mar 1;21(5):599-607. doi: 10.1111/j.1365-2036.2005.02378.x.
9
An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen.非处方剂量的酮洛芬与对乙酰氨基酚所致胃十二指肠损伤的内镜比较
Am J Gastroenterol. 1998 Jul;93(7):1051-4. doi: 10.1111/j.1572-0241.1998.00327.x.
10
Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.幽门螺杆菌感染在长期/低剂量阿司匹林治疗期间胃十二指肠损伤及胃前列腺素合成中的作用:一项前瞻性安慰剂对照双盲随机试验
Am J Gastroenterol. 2001 Jun;96(6):1751-7. doi: 10.1111/j.1572-0241.2001.03928.x.

引用本文的文献

1
Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label, prospective, observational study.对于日本原发性骨质疏松症患者,每周一次阿仑膦酸钠口服凝胶与每周一次阿仑膦酸钠口服片剂治疗的比较:一项开放标签、前瞻性、观察性研究。
Health Sci Rep. 2018 Dec 12;2(1):e107. doi: 10.1002/hsr2.107. eCollection 2019 Jan.
2
Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors.阿法骨化醇和阿仑膦酸钠对使用质子泵抑制剂的骨质疏松症患者腰椎骨密度的疗效。
Biomed Rep. 2016 Aug;5(2):165-170. doi: 10.3892/br.2016.710. Epub 2016 Jun 30.
3
A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation.
阿仑膦酸盐的可饮用制剂:提高依从性并减少上消化道刺激的潜力。
Clin Cases Miner Bone Metab. 2013 Sep;10(3):187-90.
4
Clinical development of neridronate: potential for new applications.奈立膦酸盐的临床发展:新应用的潜力。
Ther Clin Risk Manag. 2013;9:139-47. doi: 10.2147/TCRM.S35788. Epub 2013 Apr 3.
5
Optimal management of peptic ulcer disease in the elderly.老年人消化性溃疡病的最佳治疗方法。
Drugs Aging. 2010 Jul 1;27(7):545-58. doi: 10.2165/11537380-000000000-00000.
6
Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy.双膦酸盐会增加长期接受非甾体抗炎药治疗的类风湿关节炎患者发生胃十二指肠溃疡的风险。
J Gastroenterol. 2009;44(2):113-20. doi: 10.1007/s00535-008-2278-2. Epub 2009 Feb 13.
7
[Bisphosphonates and osteonecrosis of the jaw--an increasing challenge in palliative care].[双膦酸盐与颌骨骨坏死——姑息治疗中日益严峻的挑战]
Wien Med Wochenschr. 2008;158(23-24):702-6. doi: 10.1007/s10354-008-0630-z.
8
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?绝经后骨质疏松症。自双膦酸盐类药物问世以来我们学到了什么?
Rev Endocr Metab Disord. 2006 Jun;7(1-2):101-12. doi: 10.1007/s11154-006-9008-y.
9
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.双膦酸盐急性期反应:他汀类药物可抑制外周血γδ T细胞对氨基双膦酸盐产生促炎细胞因子的快速大量生成。
Clin Exp Immunol. 2005 Jan;139(1):101-11. doi: 10.1111/j.1365-2249.2005.02665.x.
10
Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.口服氯膦酸盐在原发性乳腺癌患者长期使用后的安全性概况扩展
Drug Saf. 2003;26(9):661-71. doi: 10.2165/00002018-200326090-00005.